02196.HK
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 16.20
+0.37%Year over year
Reported trailing growth
- Revenue
- +53.9%
- EBITDA
- +17.0%
- EBIT
- +0.9%
- EPS
- +57.0%
- Free cash flow
- +191.3%
- Operating cash flow
- +17.0%
Forward estimates
Based on analyst estimates
- Revenue
- -70.2%
- EBITDA
- -5.7%
- EPS
- -64.5%
Three-year CAGR
- Revenue
- -2.8%
- EBITDA
- -7.8%
- EBIT
- -32.6%
- Net income
- -4.2%
- EPS
- -4.6%
- Free cash flow
- +1045.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026